GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » Dividend-Payout-to-FFO

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Dividend-Payout-to-FFO


View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


Chongqing Genrix Biopharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Executives
Jiang Ren Sheng Director